This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Curis Hedgehog Antagonist
Roche Holding AG
Drug Names(s): G-024856, CUR-61414, Topical Hedgehog Antagonist
Description: The Curis Hedgehog Antagonist inhibits the Hedgehog Signaling Pathway, which is involved in signaling certain adjacent cells within the tumor environment to produce various growth and angiogenetic (blood vessel) forming factors that can positively influence tumor maintenance and growth.
Deal Structure: In June 2003, Curis established a collaboration with Genentech for the continued development of Curis's basal cell carcinoma product candidate. Under the terms of the collaboration, Curis retained a co-development option in the basal cell carcinoma program in the U.S. market that enables it to share in U.S. development costs and future U.S. net profits or losses in this program. On January 28, 2005, Curis elected to exercise this co-development option and will now share equally in both the U.S. development costs and any future U.S. net profits and/or losses of its basal cell carcinoma product candidate. This co-development right includes basal cell carcinoma and any additional indications for which this product candidate may be developed in the U.S. In addition, in certain international markets, Curis will receive milestones if specific clinical development objectives are achieved and a royalty on any international sales of the topical Hedgehog antagonist.
In May 2006, Curis...See full deal structure in Biomedtracker
Partners: Curis, Inc.
Curis Hedgehog Antagonist News
Additional information available to subscribers only: